2023 World Conference on Lung Cancer (Posters)-EP13.06. Exploratory Clinical Study of Anlotinib Combined with Concurrent Chemoradiotherapy in the Treatment of Small Cell Lung Cancer(SCLC)

EP13.06. Exploratory Clinical Study of Anlotinib Combined with Concurrent Chemoradiotherapy in the Treatment of Small Cell Lung Cancer(SCLC) - PDF(Slides)

Back to course

Pdf Summary

An exploratory clinical study was conducted to investigate the safety and efficacy of combining the tyrosine kinase inhibitor Anlotinib with concurrent chemoradiotherapy in the treatment of small cell lung cancer (SCLC). The study aimed to address the lack of data regarding the use of anti-angiogenesis therapy combined with chemoradiotherapy and anti-angiogenesis maintenance therapy for limited-stage and extensive-stage SCLC. Anlotinib has shown promise as an inhibitor of tumor angiogenesis and proliferation.<br /><br />The study included patients with cytologically or histologically confirmed limited-stage or extensive-stage SCLC who had not previously received systematic treatment and had an ECOG performance status of 0-2. The treatment regimen consisted of Anlotinib combined with EP/EC chemotherapy administered for at least 1 cycle. The primary endpoints of the study were progression-free survival (PFS), while secondary endpoints included overall response rate (ORR), disease control rate (DCR), overall survival (OS), and safety.<br /><br />Among the 14 patients enrolled in the study, one patient achieved a complete response (7.1%), eight patients had a partial response (57.1%), four patients had stable disease (28.6%), and one patient had progressive disease (7.1%). The ORR was 64.3% and the DCR was 92.9%. The median PFS was 14.5 months, and the median OS had not yet been reached.<br /><br />The most common treatment-related adverse events were grade 1-2 hypertension, while grade 3 adverse events included hypertension, bone marrow suppression, fever, anemia, and thrombocytopenia.<br /><br />Based on the findings, it can be concluded that the combination of Anlotinib and concurrent chemoradiotherapy demonstrates good efficacy and manageable safety in the treatment of SCLC, with no unexpected toxicity observed. Further research is currently underway.

Asset Subtitle

Fujun Yang

Meta Tag

Speaker Fujun Yang

Topic SCLC & Neuroendocrine Tumors: Preclinical

Keywords

exploratory clinical study

tyrosine kinase inhibitor

Anlotinib

concurrent chemoradiotherapy

small cell lung cancer

SCLC

anti-angiogenesis therapy

limited-stage SCLC

extensive-stage SCLC

tumor angiogenesis